Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further
Portfolio Pulse from Vandana Singh
Ventyx Biosciences' stock dropped after its Phase 2 trial for VTX958 in Crohn's disease failed to meet the primary endpoint. The company is seeking a partner to continue development.
July 29, 2024 | 3:03 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ventyx Biosciences' stock fell 24.6% after its Phase 2 trial for VTX958 in Crohn's disease did not meet the primary endpoint. The company is now looking for a partner to continue the drug's development.
The failure to meet the primary endpoint in a mid-stage trial is a significant setback for Ventyx Biosciences, leading to a sharp decline in stock price. The company's decision to seek a partner indicates challenges in continuing the development independently.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100